Sector News

Novartis, GSK shake up executive ranks as overhaul continues

October 8, 2014
Life sciences
Six months after announcing a series of deals aimed at refocusing its R&D efforts, Novartis is starting to provide some glimpses of what the new company will look like–and who will and will not be leading it. 
 
Novartis confirmed today that in the first half of next year, it expects to close the three transactions it announced on April 22–the sale of its animal health unit to Eli Lilly for $5.4 billion, the sale of most of its vaccines to GlaxoSmithKline for $7.1 billion and the formation of a joint venture with GSK to market over-the-counter products. In a press release, the company said that George Gunn, the division head of Novartis Animal Health, will retire upon the closing of the Lilly deal, and Andrin Oswald, who helmed Novartis Vaccines, will be leaving “to pursue other opportunities.” 
 
One top exec is staying: Brian McNamara, division head for Novartis OTC, who will become head of the Americas and Europe for the newly formed joint venture, called GSK Consumer Healthcare. Simultaneous to McNamara’s appointment, GSK filed a notice to the Bombay Stock Exchange announcing that the company was promoting one of its senior executives in India, Zubair Ahmed, to head up the Asia Pacific, Middle East and Africa regions for the new OTC division, according to The Financial Express. 
 
Novartis CEO Joe Jimenez has long confessed to being a big fan of consumer health products, and the JV with Glaxo is designed to maintain the company’s presence in that industry while at the same time freeing up resources to concentrate on more profitable endeavors, such as developing cancer drugs. Novartis contributed $3.5 billion in assets to the new consumer joint venture, while Glaxo put in $6.5 billion. GSK has a 63.5% stake in the JV, leaving it with managerial control. 
 
The folks charged with managing GSK Consumer Healthcare have some big brands to back them up in a competitive market, including Excedrin, Panadol and Theraflu. But that doesn’t mean consumer health will continue to be a walk in the park for GSK. In July, GSK CEO Andrew Witty–who has embarked on a slimming-down campaign for his company much like Jimenez has done at Novartis–acknowledged that spinning off the consumer health division may ultimately be the best path forward.
 
As for Novartis, it’s continuing its bid to bulk up in oncology as it pulls away from vaccines and other slower-growing endeavors. Earlier this week, Novartis said it is designing new studies of two of its experimental cancer drugs and its newly approved ALK inhibitor Zykadia, all of which will be tested in combination with Bristol-Myers Squibb’s PD-1 drug Opdivo (nivolumab). And over the summer, Novartis’ personalized CAR-T cancer therapy development program won the FDA’s coveted “breakthrough” designation. 

By Arlene Weintraub

Source: Fierce Pharma

Related News

March 6, 2021

Takeda takes full control of drug for rare epilepsies

Life sciences

The deal inked with New York-based Ovid Therapeutics carries an almost $200 million upfront payment and could be worth as much as $856 million provided the medicine, known as soticlestat, hits certain milestones. 

March 6, 2021

Novartis signs Covid-19 vaccine manufacturing agreement with CureVac

Life sciences

Novartis has entered an initial agreement to manufacture the mRNA and bulk drug product for CureVac’s Covid-19 vaccine candidate, CVnCoV.

March 6, 2021

Disney teams with Philips to bring its characters to pediatric imaging

Life sciences

A whole new world: Philips and the Walt Disney Company will use animated shorts featuring some of Disney’s most famous characters in customized stories created with clinical guidance from Philips.

Send this to a friend